Holen Sie sich die Stockscreener-App
0.333
6.14%
-0.0218
Handel nachbörslich:
.33
-0.003
-0.90%
Schlusskurs vom Vortag:
$0.3548
Offen:
$0.3381
24-Stunden-Volumen:
2.09M
Relative Volume:
1.02
Marktkapitalisierung:
$40.89M
Einnahmen:
$1.29M
Nettoeinkommen (Verlust:
$-29.87M
KGV:
-0.925
EPS:
-0.36
Netto-Cashflow:
$-14.70M
1W Leistung:
+21.98%
1M Leistung:
+10.16%
6M Leistung:
-49.62%
1J Leistung:
-47.14%
1-Tages-Spanne:
$0.33
$0.352
1-Wochen-Bereich:
$0.265
$0.3863
52-Wochen-Spanne:
$0.22
$0.94
VolitionRX Ltd Stock (VNRX) Company Profile
Firmenname
VolitionRX Ltd
Sektor
Branche
Telefon
646 650 1351
Adresse
No. 24-05 Shaw Centre, 1 Scotts Road, Singapore, TX
Vergleichen Sie VNRX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
VNRX
VolitionRX Ltd
|
0.333 | 43.57M | 1.29M | -29.87M | -14.70M | -0.36 |
|
TMO
Thermo Fisher Scientific Inc
|
618.86 | 227.87B | 43.74B | 6.58B | 6.11B | 17.31 |
|
DHR
Danaher Corp
|
238.37 | 165.99B | 24.27B | 3.50B | 5.02B | 4.8589 |
|
IDXX
Idexx Laboratories Inc
|
713.35 | 56.89B | 4.17B | 1.03B | 940.22M | 12.61 |
|
A
Agilent Technologies Inc
|
148.52 | 41.32B | 6.95B | 1.30B | 1.15B | 4.5696 |
|
IQV
Iqvia Holdings Inc
|
242.41 | 41.42B | 15.90B | 1.28B | 2.21B | 7.2842 |
VolitionRX Ltd Stock (VNRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-08 | Eingeleitet | H.C. Wainwright | Buy |
| 2023-02-01 | Herabstufung | The Benchmark Company | Buy → Hold |
| 2022-02-17 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2021-03-10 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2018-05-16 | Eingeleitet | Maxim Group | Buy |
| 2018-05-14 | Bestätigt | The Benchmark Company | Buy |
| 2016-09-07 | Bestätigt | Rodman & Renshaw | Buy |
| 2016-02-01 | Eingeleitet | Rodman & Renshaw | Buy |
Alle ansehen
VolitionRX Ltd Aktie (VNRX) Neueste Nachrichten
VolitionRX (VNRX) Receives Buy Rating, Price Target Maintained a - GuruFocus
Why VolitionRx Limited stock is popular among millennialsEarnings Growth Report & Expert Curated Trade Setups - ulpravda.ru
VolitionRx Signs Amended Securities Purchase Agreement With Lind Global Asset Management XII - TradingView — Track All Markets
Is VolitionRx Limited stock trading near support levels2025 Key Lessons & Growth Oriented Trading Recommendations - ulpravda.ru
Volitionrx stock soars after feline cancer test shows high accuracy By Investing.com - Investing.com Canada
VolitionRx secures $2 million in additional funding through convertible note By Investing.com - Investing.com India
VolitionRX announces breakthrough clinical data for Nu.Q® veterinary cancer test in cats - MarketScreener
VolitionRx secures $2M financing through amended securities agreement; shares up - MSN
VolitionRX Ltd enters amended securities purchase agreement - MarketScreener
VolitionRx Secures $2.0 Million in Funding - Yahoo Finance
A simple blood test that can spot lymphoma in cats may be on the way - Stock Titan
VolitionRx downgraded to Hold from Buy at Maxim - MSN
How buybacks impact VolitionRx Limited stock valueJuly 2025 Update & Entry and Exit Point Strategies - Улправда
How VolitionRx Limited stock performs during Fed tightening cyclesJuly 2025 Pullbacks & Fast Gain Swing Trade Alerts - Улправда
VolitionRX (VNRX) Target Price Slashed by D. Boral Capital | VNR - GuruFocus
Simple blood tests for cancer and sepsis move closer to hospitals in 2025 - Stock Titan
VolitionRx announces new paper on Capture-Seq, achieves 180-fold enrichment - MSN
VolitionRx to eliminate veterinary CEO role as part of cost-realignment - Investing.com Australia
VolitionRx Announces Termination of CEO Position at Subsidiary - TradingView — Track All Markets
VolitionRx (VNRX) to end Volition Veterinary CEO role, retain Dr. Butera as consultant - Stock Titan
VolitionRx (VNRX) Unveils Innovative Cancer Detection Method - GuruFocus
Volition (NYSE AMERICAN: VNRX) posts 100% sensitivity in 70-person liquid biopsy study - Stock Titan
VolitionRx’s (VNRX) “Buy” Rating Reaffirmed at D. Boral Capital - Defense World
Why VolitionRX Limited stock is a strong buy call2025 Pullback Review & Risk Controlled Daily Plans - Newser
VolitionRx’s Sepsis Biomarker Selected for French National Healthcare Initiative - citybuzz
VolitionRX (VNRX): Analyst Maintains 'Buy' Rating Amidst Stable Price Target | VNRX Stock News - GuruFocus
VolitionRx (NYSE AMERICAN: VNRX) named sole biomarker partner in €6.3M DETECSEPS sepsis detection program - Stock Titan
How VolitionRx Limited stock valuations compare to rivalsGap Up & Fast Entry Momentum Trade Alerts - Newser
VolitionRx (NYSE:VNRX) Lowered to “Hold” Rating by Maxim Group - Defense World
How VolitionRx Limited stock reacts to job market data2025 Market Sentiment & Consistent Growth Equity Picks - Newser
VNRX: Maxim Group Downgrades VolitionRX to Hold | VNRX Stock New - GuruFocus
Healthy Upside Potential: VolitionRX Ltd (VNRX) - Setenews
VolitionRx (VNRX) Insider Trading Activity 2025 - MarketBeat
Why millennials buy VolitionRX Limited stockQuarterly Earnings Summary & AI Optimized Trade Strategies - moha.gov.vn
VolitionRX (VNRX) Analyst Rating Update: Maintain 'Buy' with $5 Target | VNRX Stock News - GuruFocus
VolitionRX Ltd (VNRX) is looking forward to a strong quarter - Setenews
VolitionRx (VNRX) Stock Surges with First Sale of Nu.Q Cancer Assays to European Cancer Center - parameter.io
VolitionRx announces first sale of Nu.Q Cancer assays to French hospital - Investing.com India
VolitionRx announces first sale of Nu.Q Cancer assays to French hospital By Investing.com - Investing.com South Africa
Nu.Q Cancer Assays Sold for Certification at Lyon Center, VolitionRx (NYSE: VNRX) - Stock Titan
Freedom Capital Markets lowers VolitionRX stock price target on delayed revenue growth - Investing.com Australia
Freedom Capital Markets lowers VolitionRX stock price target on delayed revenue growth By Investing.com - Investing.com South Africa
Can VolitionRX Limited stock sustain breakout momentumEarnings Risk Report & Stepwise Trade Execution Plans - newser.com
Will VolitionRX Limited stock beat international competitionQuarterly Earnings Summary & Capital Efficient Trading Techniques - newser.com
What makes VolitionRx Limited stock attractive to growth fundsJuly 2025 Retail & Accurate Trade Setup Notifications - newser.com
Smart tools for monitoring VolitionRx Limited’s price actionWeekly Market Summary & Reliable Breakout Stock Forecasts - newser.com
How strong is VolitionRx Limited stock balance sheet2025 Major Catalysts & Safe Capital Growth Plans - newser.com
How VolitionRX Limited stock trades after rate cutsQuarterly Performance Summary & Expert-Curated Trade Recommendations - newser.com
H.C. Wainwright lowers VolitionRX stock price target on valuation update By Investing.com - Investing.com Nigeria
Are Smart Investors Making the Right Decision? VolitionRX Ltd (VNRX) - Setenews
H.C. Wainwright lowers VolitionRX stock price target on valuation update - Investing.com
Finanzdaten der VolitionRX Ltd-Aktie (VNRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
VolitionRX Ltd-Aktie (VNRX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Reynolds Cameron John | President and CEO |
Oct 14 '25 |
Buy |
0.51 |
110,000 |
56,100 |
2,534,847 |
| Innes Guy Archibald | Director |
Oct 14 '25 |
Buy |
0.51 |
96,153 |
49,038 |
1,062,967 |
| STILL TIMOTHY I | Director |
Oct 14 '25 |
Buy |
0.51 |
48,076 |
24,519 |
1,535,458 |
| Reynolds Cameron John | President and CEO |
Sep 12 '25 |
Buy |
0.66 |
15,000 |
9,885 |
2,624,847 |
| Innes Guy Archibald | Director |
Aug 05 '25 |
Buy |
0.64 |
78,125 |
50,000 |
966,814 |
| Reynolds Cameron John | President and CEO |
Aug 05 '25 |
Buy |
0.64 |
78,125 |
50,000 |
2,609,847 |
| Reynolds Cameron John | President and CEO |
Jun 12 '25 |
Buy |
0.59 |
12,500 |
7,372 |
2,331,722 |
| Innes Guy Archibald | Director |
Jun 03 '25 |
Buy |
0.54 |
20,000 |
10,772 |
888,689 |
| Micallef Jacob Vincent | Chief Scientific Officer |
May 19 '25 |
Buy |
0.43 |
50,000 |
21,500 |
426,033 |
| Reynolds Cameron John | President and CEO |
May 19 '25 |
Buy |
0.44 |
20,000 |
8,730 |
2,319,222 |
1.12%
0.03%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):